دورية أكاديمية

Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma

التفاصيل البيبلوغرافية
العنوان: Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma
المؤلفون: Yu H., Chen Z., Ballman K. V., Watson M. A., Govindan R., Lanc I., Beer D. G., Bueno R., Chirieac L. R., Chui M. H., Chen G., Franklin W. A., Gandara D. R., Genova C., Brovsky K. A., Joshi M. -B. M., Merrick D. T., Richards W. G., Rivard C. J., Harpole D. H., Tsao M. -S., van Bokhoven A., Shepherd F. A., Hirsch F. R.
المساهمون: Yu, H., Chen, Z., Ballman, K. V., Watson, M. A., Govindan, R., Lanc, I., Beer, D. G., Bueno, R., Chirieac, L. R., Chui, M. H., Chen, G., Franklin, W. A., Gandara, D. R., Genova, C., Brovsky, K. A., Joshi, M. -B. M., Merrick, D. T., Richards, W. G., Rivard, C. J., Harpole, D. H., Tsao, M. -S., van Bokhoven, A., Shepherd, F. A., Hirsch, F. R.
بيانات النشر: Elsevier Inc
360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
سنة النشر: 2019
المجموعة: Università degli Studi di Genova: CINECA IRIS
مصطلحات موضوعية: Early-stage squamous cell lung cancer, Immune gene signature, PD-L1 expression, Prognosi, Tumor mutation burden, Aged, B7-H1 Antigen, Carcinoma, Squamous Cell, Female, Human, Interferon-gamma, Lung Neoplasm, Male, Mutation, Neoplasm Staging, Tumor Burden
الوصف: Objectives: Anti–programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) immunotherapy has demonstrated success in the treatment of advanced NSCLC. Recently, PD-1/PD-L1 blockade also has demonstrated interesting results in small trials of neoadjuvant treatment in stage IB to IIIA NSCLC. In addition, several clinical trials using anti–PD-1/PD-L1 immunotherapy as an adjuvant or neoadjuvant treatment in patients with resectable stage NSCLC are ongoing. However, few analyses of anti–PD-1/PD-L1 immunotherapy–related biomarkers in early-stage squamous cell lung carcinoma (SqCLC) have been reported. In this study, we evaluated PD-L1 protein expression, tumor mutation burden, and expression of an immune gene signature in early-stage SqCLC, providing data for identifying the potential role for patients with anti–PD-1/PD-L1 treatment in early-stage SqCLC. Methods: A total of 255 specimens from patients with early-stage SqCLC were identified within participating centers of the Strategic Partnering to Evaluate Cancer Signatures program. PD-L1 protein expression by immunohistochemistry was evaluated by using the Dako PD-L1 22C3 pharmDx kit on the Dako Link 48 auto-stainer (Dako, Carpinteria, CA). Tumor mutation burden (TMB) was calculated on the basis of data from targeted genome sequencing. The T-effector and interferon gamma (IFN-γ) gene signature was determined from Affymetrix gene chip data (Affymetrix, Santa Clara, CA) from frozen specimens. Results: The prevalence of PD-L1 expression was 9.8% at a tumor proportion score cutoff of at least 50%. PD-L1 mRNA and programmed cell death 1 ligand 2 mRNA positively correlated with PD-L1 protein expression on tumor cells (TCs) and tumor-infiltrating immune cells. PD-L1 protein expression on tumor-infiltrating immune cells was correlated with the T-effector and IFN-γ gene signature (p < 0.001), but not with TMB. For TCs, all of these biomarkers were independent of each other and neither PD-L1 protein expression, TMB, or T-effector and IFN-γ gene signatures were ...
نوع الوثيقة: article in journal/newspaper
وصف الملف: ELETTRONICO
اللغة: English
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/30253973; info:eu-repo/semantics/altIdentifier/wos/WOS:000454018600016; volume:14; firstpage:25; lastpage:36; numberofpages:12; journal:JOURNAL OF THORACIC ONCOLOGY; https://hdl.handle.net/11567/1028981Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85056474859
DOI: 10.1016/j.jtho.2018.09.006
الإتاحة: https://doi.org/10.1016/j.jtho.2018.09.006Test
https://hdl.handle.net/11567/1028981Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.FB13821F
قاعدة البيانات: BASE